Electrophysiological evaluation of pentamidine and 17-AAG in human stem cell-derived cardiomyocytes for safety assessment

Yumiko Asahi, Fumimasa Nomura, Yasuyuki Abe, Masafumi Doi, Tomoko Sakakura, Kiyoshi Takasuna, Kenji Yasuda

    研究成果: Article

    抄録

    Human ether-a-go-go-related gene (hERG) trafficking inhibition is known to be one of the mechanisms of indirect hERG inhibition, resulting in QT prolongation and lethal arrhythmia. Pentamidine, an antiprotozoal drug, causes QT prolongation/Torsades de Pointes (TdP) via hERG trafficking inhibition, but 17-AAG, a geldanamycin derivative heat shock protein 90 (Hsp90) inhibitor, has not shown torsadogenic potential clinically, despite Hsp90 inhibitors generally being hypothesized to cause TdP by hERG trafficking inhibition. In the present study, we investigated the underlying mechanisms of both drugs’ actions on hERG channels using hERG-overexpressing CHO cells (hERG-CHOs) and human embryonic stem cell-derived cardiomyocytes (hES-CMs). The effects on hERG tail current and protein levels were evaluated using population patch clamp and Western blotting in hERG-CHOs. The effects on field potential duration (FPD) were recorded by a multi-electrode array (MEA) in hES-CMs. Neither drug affected hERG tail current acutely. Chronic treatment with each drug inhibited hERG tail current and decreased the mature form of hERG protein in hERG-CHOs, whereas the immature form of hERG protein was increased by pentamidine but decreased by 17-AAG. In MEA assays using hES-CMs, pentamidine time-dependently prolonged FPD, but 17-AAG shortened it. The FPD prolongation in hES-CMs upon chronic pentamidine exposure is relevant to its clinically reported arrhythmic risk. Cav1.2 or Nav1.5 current were not reduced by chronic application of either drug at a relevant concentration to hERG trafficking inhibition in human embryonic kidney (HEK293) cells. Therefore, the reason why chronic 17-AAG shortened the FPD despite the hERG trafficking inhibition occur is still unknown.

    元の言語English
    ページ(範囲)221-230
    ページ数10
    ジャーナルEuropean Journal of Pharmacology
    842
    DOI
    出版物ステータスPublished - 2019 1 5

    Fingerprint

    tanespimycin
    Pentamidine
    Cardiac Myocytes
    Ether
    Stem Cells
    Safety
    Genes
    HSP90 Heat-Shock Proteins
    Tail
    Torsades de Pointes
    Pharmaceutical Preparations
    Electrodes

    ASJC Scopus subject areas

    • Pharmacology

    これを引用

    Electrophysiological evaluation of pentamidine and 17-AAG in human stem cell-derived cardiomyocytes for safety assessment. / Asahi, Yumiko; Nomura, Fumimasa; Abe, Yasuyuki; Doi, Masafumi; Sakakura, Tomoko; Takasuna, Kiyoshi; Yasuda, Kenji.

    :: European Journal of Pharmacology, 巻 842, 05.01.2019, p. 221-230.

    研究成果: Article

    Asahi, Yumiko ; Nomura, Fumimasa ; Abe, Yasuyuki ; Doi, Masafumi ; Sakakura, Tomoko ; Takasuna, Kiyoshi ; Yasuda, Kenji. / Electrophysiological evaluation of pentamidine and 17-AAG in human stem cell-derived cardiomyocytes for safety assessment. :: European Journal of Pharmacology. 2019 ; 巻 842. pp. 221-230.
    @article{521ff5ca708f4eef8f97c07a01b9a4ce,
    title = "Electrophysiological evaluation of pentamidine and 17-AAG in human stem cell-derived cardiomyocytes for safety assessment",
    abstract = "Human ether-a-go-go-related gene (hERG) trafficking inhibition is known to be one of the mechanisms of indirect hERG inhibition, resulting in QT prolongation and lethal arrhythmia. Pentamidine, an antiprotozoal drug, causes QT prolongation/Torsades de Pointes (TdP) via hERG trafficking inhibition, but 17-AAG, a geldanamycin derivative heat shock protein 90 (Hsp90) inhibitor, has not shown torsadogenic potential clinically, despite Hsp90 inhibitors generally being hypothesized to cause TdP by hERG trafficking inhibition. In the present study, we investigated the underlying mechanisms of both drugs’ actions on hERG channels using hERG-overexpressing CHO cells (hERG-CHOs) and human embryonic stem cell-derived cardiomyocytes (hES-CMs). The effects on hERG tail current and protein levels were evaluated using population patch clamp and Western blotting in hERG-CHOs. The effects on field potential duration (FPD) were recorded by a multi-electrode array (MEA) in hES-CMs. Neither drug affected hERG tail current acutely. Chronic treatment with each drug inhibited hERG tail current and decreased the mature form of hERG protein in hERG-CHOs, whereas the immature form of hERG protein was increased by pentamidine but decreased by 17-AAG. In MEA assays using hES-CMs, pentamidine time-dependently prolonged FPD, but 17-AAG shortened it. The FPD prolongation in hES-CMs upon chronic pentamidine exposure is relevant to its clinically reported arrhythmic risk. Cav1.2 or Nav1.5 current were not reduced by chronic application of either drug at a relevant concentration to hERG trafficking inhibition in human embryonic kidney (HEK293) cells. Therefore, the reason why chronic 17-AAG shortened the FPD despite the hERG trafficking inhibition occur is still unknown.",
    keywords = "17-AAG, Arrhythmia, hERG trafficking, Hsp90 inhibitor, Human embryonic stem cell derived-cardiomyocytes (hES-CMs), Multi-electrode array (MEA)",
    author = "Yumiko Asahi and Fumimasa Nomura and Yasuyuki Abe and Masafumi Doi and Tomoko Sakakura and Kiyoshi Takasuna and Kenji Yasuda",
    year = "2019",
    month = "1",
    day = "5",
    doi = "10.1016/j.ejphar.2018.10.046",
    language = "English",
    volume = "842",
    pages = "221--230",
    journal = "European Journal of Pharmacology",
    issn = "0014-2999",
    publisher = "Elsevier",

    }

    TY - JOUR

    T1 - Electrophysiological evaluation of pentamidine and 17-AAG in human stem cell-derived cardiomyocytes for safety assessment

    AU - Asahi, Yumiko

    AU - Nomura, Fumimasa

    AU - Abe, Yasuyuki

    AU - Doi, Masafumi

    AU - Sakakura, Tomoko

    AU - Takasuna, Kiyoshi

    AU - Yasuda, Kenji

    PY - 2019/1/5

    Y1 - 2019/1/5

    N2 - Human ether-a-go-go-related gene (hERG) trafficking inhibition is known to be one of the mechanisms of indirect hERG inhibition, resulting in QT prolongation and lethal arrhythmia. Pentamidine, an antiprotozoal drug, causes QT prolongation/Torsades de Pointes (TdP) via hERG trafficking inhibition, but 17-AAG, a geldanamycin derivative heat shock protein 90 (Hsp90) inhibitor, has not shown torsadogenic potential clinically, despite Hsp90 inhibitors generally being hypothesized to cause TdP by hERG trafficking inhibition. In the present study, we investigated the underlying mechanisms of both drugs’ actions on hERG channels using hERG-overexpressing CHO cells (hERG-CHOs) and human embryonic stem cell-derived cardiomyocytes (hES-CMs). The effects on hERG tail current and protein levels were evaluated using population patch clamp and Western blotting in hERG-CHOs. The effects on field potential duration (FPD) were recorded by a multi-electrode array (MEA) in hES-CMs. Neither drug affected hERG tail current acutely. Chronic treatment with each drug inhibited hERG tail current and decreased the mature form of hERG protein in hERG-CHOs, whereas the immature form of hERG protein was increased by pentamidine but decreased by 17-AAG. In MEA assays using hES-CMs, pentamidine time-dependently prolonged FPD, but 17-AAG shortened it. The FPD prolongation in hES-CMs upon chronic pentamidine exposure is relevant to its clinically reported arrhythmic risk. Cav1.2 or Nav1.5 current were not reduced by chronic application of either drug at a relevant concentration to hERG trafficking inhibition in human embryonic kidney (HEK293) cells. Therefore, the reason why chronic 17-AAG shortened the FPD despite the hERG trafficking inhibition occur is still unknown.

    AB - Human ether-a-go-go-related gene (hERG) trafficking inhibition is known to be one of the mechanisms of indirect hERG inhibition, resulting in QT prolongation and lethal arrhythmia. Pentamidine, an antiprotozoal drug, causes QT prolongation/Torsades de Pointes (TdP) via hERG trafficking inhibition, but 17-AAG, a geldanamycin derivative heat shock protein 90 (Hsp90) inhibitor, has not shown torsadogenic potential clinically, despite Hsp90 inhibitors generally being hypothesized to cause TdP by hERG trafficking inhibition. In the present study, we investigated the underlying mechanisms of both drugs’ actions on hERG channels using hERG-overexpressing CHO cells (hERG-CHOs) and human embryonic stem cell-derived cardiomyocytes (hES-CMs). The effects on hERG tail current and protein levels were evaluated using population patch clamp and Western blotting in hERG-CHOs. The effects on field potential duration (FPD) were recorded by a multi-electrode array (MEA) in hES-CMs. Neither drug affected hERG tail current acutely. Chronic treatment with each drug inhibited hERG tail current and decreased the mature form of hERG protein in hERG-CHOs, whereas the immature form of hERG protein was increased by pentamidine but decreased by 17-AAG. In MEA assays using hES-CMs, pentamidine time-dependently prolonged FPD, but 17-AAG shortened it. The FPD prolongation in hES-CMs upon chronic pentamidine exposure is relevant to its clinically reported arrhythmic risk. Cav1.2 or Nav1.5 current were not reduced by chronic application of either drug at a relevant concentration to hERG trafficking inhibition in human embryonic kidney (HEK293) cells. Therefore, the reason why chronic 17-AAG shortened the FPD despite the hERG trafficking inhibition occur is still unknown.

    KW - 17-AAG

    KW - Arrhythmia

    KW - hERG trafficking

    KW - Hsp90 inhibitor

    KW - Human embryonic stem cell derived-cardiomyocytes (hES-CMs)

    KW - Multi-electrode array (MEA)

    UR - http://www.scopus.com/inward/record.url?scp=85056534158&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85056534158&partnerID=8YFLogxK

    U2 - 10.1016/j.ejphar.2018.10.046

    DO - 10.1016/j.ejphar.2018.10.046

    M3 - Article

    VL - 842

    SP - 221

    EP - 230

    JO - European Journal of Pharmacology

    JF - European Journal of Pharmacology

    SN - 0014-2999

    ER -